Differential miRNA expression profile and proteome in plasma exosomes from patients with paroxysmal nocturnal hemoglobinuria
Autor: | Nuria García-Barberá, Irene Martínez-Martínez, Juan Carlos Espín, Salvador Espín, Jose Yuste, Raúl Teruel-Montoya, Constantino Martínez, Fernando Vallejo, Nataliya Bohdan, Ginés Luengo-Gil, Vicente Vicente |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2019 |
Předmět: |
0301 basic medicine
Hemolytic anemia Male Adolescent Proteome Hemoglobinuria Paroxysmal lcsh:Medicine Exosomes Article 03 medical and health sciences 0302 clinical medicine medicine Humans lcsh:Science Aged Multidisciplinary biology business.industry Haptoglobin lcsh:R Bone marrow failure Eculizumab Middle Aged medicine.disease Microvesicles Complement system MicroRNAs 030104 developmental biology Case-Control Studies Immunology Paroxysmal nocturnal hemoglobinuria biology.protein Hemoglobinuria Female lcsh:Q business 030217 neurology & neurosurgery Biomarkers medicine.drug |
Zdroj: | Scientific Reports, Vol 9, Iss 1, Pp 1-8 (2019) Scientific Reports |
ISSN: | 2045-2322 |
Popis: | Paroxysmal Nocturnal Hemoglobinuria (PNH) is a clonal disease of blood cells caused by the lack of glycosyl phosphatidyl inositol anchored proteins bound to the cell membrane. In consequence, erythrocytes lead to intravascular hemolysis upon complement activation, which promotes high risk of thrombosis, intravascular hemolytic anemia, and bone marrow failure in patients. The mechanisms of thrombosis in PNH are still poorly understood. Treatment with eculizumab reduces intravascular hemolysis and thrombotic risk, but not in all cases. Exosomes are extracellular vesicles released by cells and whose secretion is closely related to the inflammatory status. They participate in cell communication by activating signaling pathways and transferring genetic material and proteins to host cells. In consequence, exosomes may serve as surrogate biomarkers for the prognosis and/or diagnosis of a disease. Isolation of exosomes was carried out from healthy controls and from three groups of PNH patients, i.e. i) with no eculizumab treatment; ii) under treatment with eculizumab that have not suffered thrombosis; and iii) under treatment with eculizumab but that have suffered thrombosis. The miRNAome and proteome was analyzed using plasma focus miRNAs PCR panel and LC-MS analysis respectively. We found differential expression of miRNAs miR-148b-3p, miR-423-3p, miR29b-3p, miR15b-5p, let-7e-5p, miR126-3p, miR-125b-5p and miR-376c-3p as well as hemoglobin, haptoglobin, protein S and C4-binding protein in healthy controls vs PNH patients. Our results warrant further research and provide new information on the content of exosomes that could play a role in the hypercoagulable state in this disease. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |